In cardio-metabolic diseases both the coronary circulation and cardiac metabolism are altered. We have studied a condition called hyperhomocysteinemia (HHcy), which can develop as a result of genetic or environmental causes. This metabolic disease is underappreciated, yet even mild or moderate elevation of plasma concentrations of homocystein (Hcy, a sulfur-containing amino acid produced via methionine metabolism) leads to coronary and peripheral arterial and vascular diseases, increased thrombosis and consequently increased mortality. The underlying mechanisms have not been revealed yet. Our recent studies indicate that there are common pathomechanisms, which may affect all of the cellular functions involved. We have shown that a dysfunction of nitric oxide (NO) mediation of dilator responses in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia develops (Arterioscler Thromb Vasc Biol. 1999; 19(8):1899-904) with simultaneously increased TXA2 the activity in arterioles and platelets (Arterioscler Thromb Vasc Biol. 2000; 20(5): 1203-8 2010;208( 1):43-9) . The alteration in the endothelial function affected the ability of NO to regulate cardiac metabolism as we have found that elevated levels of p22phox, p67phox, and rac-1 indicate an increased NADPH oxidase assembly resulting in an increased superoxide production and in a reduced ability of NO to regulate the mitochondrial function in the myocardium (Circulation. 2005; 111(16):2112-8.) . The interaction of these pathomechanisms explain why HHcy increases the uptake of glucose and lactate and decreases the uptake of free fatty acid by the heart (Circulation. 2007; 115(2):255-62) . Similar alterations could play a role in the development of cardio-metabolic and coronary dysfunction in other metabolic diseases, such as diabetes mellitus, hyperlipidemia and metabolic syndrome. 
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